Checkpoint Therapeutics (CKPT) 10-Q4 Nov 212021 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Nov. 02, 2021
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-38128
Entity Registrant Name	CHECKPOINT THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-2568632
Entity Address, Address Line One	95 Sawyer Road
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	781
Local Phone Number	652-4500
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CKPT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Central Index Key	0001651407
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Class A Common Shares [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		7,000,000
Common Shares [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		76,773,146

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 60,203	$ 40,772
Prepaid expenses and other assets	737	1,804
Other receivables - related party	29	20
Total current assets	60,969	42,596
Total Assets	60,969	42,596
Current Liabilities:
Accounts payable and accrued expenses	12,064	6,367
Accounts payable and accrued expenses - related party	936	850
Total current liabilities	13,000	7,217
Total Liabilities	13,000	7,217
Commitments and Contingencies
Stockholders' Equity
Common stock issuable, 0 and 1,742,449 shares as of September 30, 2021 and December 31, 2020, respectively		4,617
Additional paid-in capital	218,066	173,947
Accumulated deficit	170,106	143,192
Total Stockholders' Equity	47,969	35,379
Total Liabilities and Stockholders' Equity	60,969	42,596
Common No Class [Member]
Stockholders' Equity
Common Stock Value	8	6
Class A Common Shares [Member]
Stockholders' Equity
Common Stock Value	$ 1	$ 1

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	135,000,000	95,000,000
Common Stock, Shares, Issued	76,214,398	62,420,439
Common Stock, Shares, Outstanding	76,214,398	62,420,439
Common Stock, Shares Subscribed but Unissued	0	1,742,449
Class A Common Shares [Member]
Common Stock, Shares, Issued	7,000,000	7,000,000
Common Stock, Shares, Outstanding	7,000,000	7,000,000

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Condensed Statements of Operations - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Statements of Operations
Revenue - related party	$ 29	$ 28	$ 252	$ 1,042
Operating expenses:
Research and development	9,384	2,543	20,795	8,207
General and administrative	1,923	2,429	6,410	5,794
Total operating expenses	11,307	4,972	27,205	14,001
Loss from operations	(11,278)	(4,944)	(26,953)	(12,959)
Other income
Interest income	13	14	39	103
Total other income	13	14	39	103
Net Loss	$ (11,265)	$ (4,930)	$ (26,914)	$ (12,856)
Loss per Share:
Basic net loss per common share outstanding	$ (0.14)	$ (0.09)	$ (0.36)	$ (0.24)
Basic weighted average number of common shares outstanding	78,530,952	56,405,734	74,805,868	53,040,215

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity - USD ($)	Common Shares [Member]Class A Common Shares [Member]	Common Shares [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balances at Dec. 31, 2019	$ 1,000	$ 5,000	$ 2,510,000	$ 136,442,000	$ (120,111,000)	$ 18,847,000
Balances (in Shares) at Dec. 31, 2019	7,000,000	47,004,764
Issuance of common shares, net of offering costs - At-the-market offering	$ 0	$ 0	0	8,417,000	0	8,417,000
Issuance of common shares, net of offering costs - At-the-market offering (in Shares)	0	3,614,344
Issuance of common shares, net of offering costs - Public offering	$ 0	$ 1,000	0	18,911,000	0	18,912,000
Issuance of common shares, net of offering costs - Public offering (in Shares)	0	7,321,429
Issuance of common shares - Founders Agreement	$ 0	$ 0	(2,510,000)	3,307,000	0	797,000
Issuance of common shares - Founders Agreement (in Shares)	0	1,732,684
Stock-based compensation expense	$ 0	$ 0	0	2,095,000	0	2,095,000
Stock-based compensation expense (in Shares)	0	1,107,340
Exercise of warrants	$ 0	$ 0	0	13,000	0	13,000
Exercise of warrants (in Shares)	0	102,742
Net loss	$ 0	$ 0	0	0	(12,856,000)	(12,856,000)
Balances at Sep. 30, 2020	$ 1,000	$ 6,000	0	169,185,000	(132,967,000)	36,225,000
Balances (in Shares) at Sep. 30, 2020	7,000,000	60,883,303
Balances at Jun. 30, 2020	$ 1,000	$ 5,000	0	143,005,000	(128,037,000)	14,974,000
Balances (in Shares) at Jun. 30, 2020	7,000,000	50,980,004
Issuance of common shares, net of offering costs - At-the-market offering	$ 0	$ 0	0	5,813,000	0	5,813,000
Issuance of common shares, net of offering costs - At-the-market offering (in Shares)	0	2,311,062
Issuance of common shares, net of offering costs - Public offering	$ 0	$ 1,000	0	18,911,000	0	18,912,000
Issuance of common shares, net of offering costs - Public offering (in Shares)	0	7,321,429
Issuance of common shares - Founders Agreement	$ 0	$ 0	0	731,000	0	731,000
Issuance of common shares - Founders Agreement (in Shares)	0	240,808
Stock-based compensation expense	$ 0	$ 0	0	725,000	0	725,000
Stock-based compensation expense (in Shares)	0	30,000
Net loss	$ 0	$ 0	0	0	(4,930,000)	(4,930,000)
Balances at Sep. 30, 2020	$ 1,000	$ 6,000	0	169,185,000	(132,967,000)	36,225,000
Balances (in Shares) at Sep. 30, 2020	7,000,000	60,883,303
Balances at Dec. 31, 2020	$ 1,000	$ 6,000	4,617,000	173,947,000	(143,192,000)	35,379,000
Balances (in Shares) at Dec. 31, 2020	7,000,000	62,420,439
Issuance of common shares, net of offering costs - At-the-market offering	$ 0	$ 2,000	0	36,257,000	0	36,259,000
Issuance of common shares, net of offering costs - At-the-market offering (in Shares)	0	10,860,983
Issuance of common shares - Founders Agreement	$ 0	$ 0	(4,617,000)	5,543,000	0	926,000
Issuance of common shares - Founders Agreement (in Shares)	0	2,013,964
Stock-based compensation expense	$ 0	$ 0	0	2,319,000	0	2,319,000
Stock-based compensation expense (in Shares)	0	919,012
Net loss	$ 0	$ 0	0	0	(26,914,000)	(26,914,000)
Balances at Sep. 30, 2021	$ 1,000	$ 8,000	0	218,066,000	(170,106,000)	47,969,000
Balances (in Shares) at Sep. 30, 2021	7,000,000	76,214,398
Balances at Jun. 30, 2021	$ 1,000	$ 8,000	0	215,706,000	(158,841,000)	56,874,000
Balances (in Shares) at Jun. 30, 2021	7,000,000	75,741,873
Issuance of common shares, net of offering costs - At-the-market offering	$ 0	$ 0	0	1,542,000	0	1,542,000
Issuance of common shares, net of offering costs - At-the-market offering (in Shares)	0	461,000
Issuance of common shares - Founders Agreement	$ 0	$ 0	0	39,000	0	39,000
Issuance of common shares - Founders Agreement (in Shares)	0	11,525
Stock-based compensation expense	$ 0	$ 0	0	779,000	0	779,000
Stock-based compensation expense (in Shares)	0	0
Net loss	$ 0	$ 0	0	0	(11,265,000)	(11,265,000)
Balances at Sep. 30, 2021	$ 1,000	$ 8,000	$ 0	$ 218,066,000	$ (170,106,000)	$ 47,969,000
Balances (in Shares) at Sep. 30, 2021	7,000,000	76,214,398

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Cash Flows from Operating Activities:
Net loss	$ (26,914)	$ (12,856)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,319	2,095
Issuance of common shares - Founders Agreement	926	797
Changes in operating assets and liabilities:
Prepaid expenses and other assets	1,067	275
Other receivables - related party	(9)	(2)
Accounts payable and accrued expenses	5,783	(1,926)
Net cash used in operating activities	(16,828)	(11,617)
Cash Flows from Financing Activities:
Issuance of common shares - Public offering	0	20,500
Offering costs for the issuance of common stock - Public offering	0	(1,361)
Proceeds from issuance of common stock - At-the-market offering	37,187	8,684
Offering costs for the issuance of common stock - At-the-market offering	(928)	(267)
Proceeds from the exercise of warrants	0	13
Net cash provided by financing activities	36,259	27,569
Net increase in cash and cash equivalents	19,431	15,952
Cash and cash equivalents at beginning of period	40,772	26,077
Cash and cash equivalents at end of period	60,203	42,029
Supplemental disclosure of noncash investing and financing activities:
Issuance of common shares - Founders Agreement	4,617	2,510
Issuance of common shares - Public offering (offering costs incurred but not paid)	$ 0	$ 296

Organization and Description of

Organization and Description of Business Operations	9 Months Ended
Organization and Description of Business Operations	Sep. 30, 2021
Organization and Description of Business Operations
Organization and Description of Business Operations	Note 1 - Organization and Description of Business Operations Checkpoint Therapeutics, Inc. (the “Company” or “Checkpoint”) was incorporated in Delaware on November 10, 2014. Checkpoint is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company may also enter into collaboration agreements with third and related parties including sponsored research agreements to develop these technologies for liquid tumors while retaining the rights in solid tumors. The Company is a majority-controlled subsidiary of Fortress Biotech, Inc. (“Fortress”). The Company’s common stock is listed on the NASDAQ Capital Market and trades under the symbol “CKPT.” Liquidity and Capital Resources The Company has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2021, the Company had an accumulated deficit of $170.1 million. During the nine months ended September 30, 2021, the Company sold a total of 10,860,983 shares of common stock under an At-the-Market Issuance Sales Agreement (“ATM”), at an average selling price of $3.42 per share, resulting in aggregate total gross proceeds of approximately $37.2 million and net proceeds of approximately $36.3 million after deducting approximately $0.9 million in commissions and other transaction costs. The Company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes, which may include financing the Company’s growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. The Company currently anticipates that its cash and cash equivalents balances at September 30, 2021 will be sufficient to fund its anticipated operating cash requirements for at least one year from the filing date of this Quarterly Report on Form 10-Q. The Company will be required to expend significant funds in order to advance the development of its product candidates. The Company’s estimate as to how long it expects its existing cash to be able to continue to fund its operations is based on assumptions that may prove to be wrong, and it could use its available capital resources sooner than it currently expects. Further, changing circumstances, some of which may be beyond its control, could cause the Company to consume capital faster than it currently anticipates, and it may need to seek additional funds sooner than planned. Accordingly, the Company will be required to obtain further funding through equity offerings, debt financings, collaborations and licensing arrangements or other sources. Further financing may not be available to it on acceptable terms, or at all. The Company’s failure to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategy and may be forced to curtail or cease operations. Based on the Company’s current assessment, the Company does not expect any material impact on its long-term development timeline and its liquidity due to the worldwide spread of the coronavirus (“COVID-19”). However, the Company is continuing to assess the effects of the COVID-19 pandemic on the Company’s operations, as well as on the Company’s clients, vendors, and business partners, and the actions implemented to combat the virus throughout the world.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
Significant Accounting Policies	Sep. 30, 2021
Significant Accounting Policies
Significant Accounting Policies	Note 2 - Significant Accounting Policies Basis of Presentation The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Exchange Act. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. They may not include all of the information and notes required by GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2020, which were included in the Company’s Form 10-K, and filed with the SEC on March 12, 2021. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Other Receivables - Related Party Other receivables consist of amounts due to the Company from TG Therapeutics, Inc. (“TGTX”), a related party, and are recorded at the invoiced amount. Research and Development Costs Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies. In accordance with Accounting Standards Codification (“ASC”) 730-10-25-1, Research and Development Annual Equity Fee Under the Founders Agreement with Checkpoint dated March 17, 2015, and amended and restated in July 2016 and October 2017 (the “Founders Agreement”), Fortress is entitled to an annual equity fee on January 1 of each year equal to 2.5% of fully diluted outstanding equity, payable in Checkpoint common shares (“Annual Equity Fee”). The Annual Equity Fee was part of the consideration payable for formation of the Company, identification of certain assets, including the license contributed to Checkpoint by Fortress (see Note 4). The Company records the Annual Equity Fee in connection with the Founders Agreement with Fortress as contingent consideration. Contingent consideration is recorded when probable and reasonably estimable. Due to the nature of the Company’s assets and stage of development, future share prices and shares outstanding cannot be estimated prior to the issuance of the Annual Equity Fee. Due to these uncertainties, the Company has concluded that it is unable to reasonably estimate the contingent consideration until shares are actually issued on January 1 of each year. Pursuant to the Founders Agreement, the Company issued 1,742,449 shares of common stock to Fortress for the Annual Equity Fee, representing 2.5% of the fully diluted outstanding equity of Checkpoint on January 1, 2021. Because the number of outstanding shares issuable to Fortress was determinable on January 1, 2021 prior to the issuance of the December 31, 2020 financial statements, the Company recorded approximately $4.6 million in research and development expense and a credit to Common shares issuable - Founders Agreement during the year ended December 31, 2020. Stock-Based Compensation Expenses The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the Condensed Statements of Operations based upon the underlying individual’s role at the Company. Fair Value Measurement The Company follows the accounting guidance in ASC 820 for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable and accrued expenses. Revenue from Contracts with Customers The Company recognizes revenue under ASC 606, “ Revenue from Contracts with Customers ● Step 1: Identify the contract with the customer. ● Step 2: Identify the performance obligations in the contract. ● Step 3: Determine the transaction price. ● Step 4: Allocate the transaction price to the performance obligations in the contract. ● Step 5: Recognize revenue when the company satisfies a performance obligation. In order to identify the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or service that is distinct. A performance obligation meets ASC 606’s definition of a “distinct” good or service (or bundle of goods or services) if both of the following criteria are met: ● the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and ● the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. When determining the transaction price, an entity must consider the effects of all of the following: ● variable consideration; ● constraining estimates of variable consideration; ● the existence of a significant financing component in the contract; ● noncash consideration; and ● consideration payable to a customer. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized when that performance obligation is satisfied, at a point in time or over time as appropriate. Revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property is recognized only when (or as) the later of the following events occurs: a. the subsequent sale or usage occurs; and b. the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). Incremental contract costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as services are provided to a customer. Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not to be sustained upon audit, the Company recognizes the largest amount with a greater than 50% likelihood of being realized. The Company does not recognize any portion of the benefit for tax positions that are not more likely than not to be sustained upon audit. As of September 30, 2021 and December 31, 2020, the Company determined, based upon available evidence, that it is more likely than not that the net deferred tax asset will not be realized and, accordingly, has provided a full valuation allowance against its net deferred tax asset. Net Loss per Share Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class A common stock pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of stock options and warrants, as their inclusion would be anti-dilutive. The following table summarizes potentially dilutive securities outstanding at September 30, 2021 and 2020 that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive: September 30, 2021 2020 Warrants (Note 6) 13,191 3,224,455 Stock options (Note 6) 270,000 220,000 Unvested restricted stock (Note 6) 4,240,868 4,013,199 Total 4,524,059 7,457,654 Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. The CARES Act did not have a material impact on the Company’s income tax provision. The Company will continue to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows. On December 27, 2020, the President of the United States signed the Consolidated Appropriations Act, 2021 (“Consolidated Appropriations Act”) into law. The Consolidated Appropriations Act is intended to enhance and expand certain provisions of the CARES Act, allows for the deductions of expenses related to the Payroll Protection Program funds received by companies, and provides an update to meals and entertainment expensing for 2021. The Consolidated Appropriations Act did not have a material impact to the Company’s income tax provision for 2020 and the Company does not believe it will have a material impact on its income tax provision for 2021. The Company will continue to evaluate the impact of the Consolidated Appropriations Act on its financial position, results of operations and cash flows. Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “ Financial Instruments – Credit Losses In August 2020, the FASB issued ASU No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Recently Adopted Accounting Standards In December 2019, the FASB issued ASU No. 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

License Agreements

License Agreements	9 Months Ended
License Agreements	Sep. 30, 2021
License Agreements
License Agreements	Note 3 – License Agreements Dana-Farber Cancer Institute In March 2015, the Company entered into an exclusive license agreement with Dana-Farber Cancer Institute (“Dana Farber”) to develop a portfolio of fully human immuno-oncology targeted antibodies. Under the terms of the license agreement, the Company paid Dana-Farber an up-front licensing fee of $1.0 million and, on May 11, 2015, granted Dana-Farber 500,000 shares of common stock, valued at $32,500 or $0.065 per share. The license agreement included an anti-dilution clause that maintained Dana-Farber’s ownership at 5% until such time that the Company raised $10 million in cash in exchange for common shares. Pursuant to this provision, on September 30, 2015, the Company granted to Dana-Farber an additional 136,830 shares of common stock valued at approximately $0.6 million and the anti-dilution clause thereafter expired. Dana-Farber is eligible to receive payments of up to an aggregate of approximately $21.5 million for each licensed product upon the Company’s successful achievement of certain clinical development, regulatory and first commercial sale milestones. In addition, Dana-Farber is eligible to receive up to an aggregate of $60.0 million upon the Company’s successful achievement of certain sales milestones based on aggregate net sales, in addition to royalty payments based on a tiered low to mid-single digit percentage of net sales. Dana-Farber also receives an annual license maintenance fee of $50,000, which is creditable against future milestone payments or royalties. The portfolio of antibodies licensed from Dana-Farber include antibodies targeting PD-L1, GITR and CAIX. In connection with the license agreement with Dana-Farber, the Company entered into a collaboration agreement with TGTX, which was amended and restated in June 2019, to develop and commercialize the anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies, while the Company retains the right to develop and commercialize these antibodies in solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and Fortress’ Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the original collaboration agreement, TGTX paid the Company $0.5 million, representing an upfront licensing fee. Upon the signing of the amended and restated collaboration agreement in June 2019, TGTX paid the Company an additional $1.0 million upfront licensing fee. The Company is eligible to receive substantive potential milestone payments for the anti-PD-L1 program of up to an aggregate of approximately $27.6 million upon TGTX’s successful achievement of certain clinical development, regulatory and first commercial sale milestones. This is comprised of up to approximately $8.4 million upon TGTX’s successful completion of clinical development milestones, and up to approximately $19.2 million upon regulatory filings and first commercial sales in specified territories. The Company is also eligible to receive substantive potential milestone payments for the anti-GITR antibody program of up to an aggregate of approximately $21.5 million upon TGTX’s successful achievement of certain clinical development, regulatory and first commercial sale milestones. This is comprised of up to approximately $7.0 million upon TGTX’s successful completion of clinical development milestones, and up to approximately $14.5 million upon first commercial sales in specified territories. In addition, the Company is eligible to receive up to an aggregate of $60.0 million upon TGTX’s successful achievement of certain sales milestones based on aggregate net sales for both programs, in addition to royalty payments based on a tiered low double-digit percentage of net sales. The Company also receives an annual license maintenance fee, which is creditable against future milestone payments or royalties. TGTX also pays the Company for its out-of-pocket costs of material used by TGTX for their development activities. For the three months ended September 30, 2021 and 2020, the Company recognized approximately $1,000 and $7,000, respectively, in revenue related to the collaboration agreement in the Condensed Statements of Operations. For the nine months ended September 30, 2021 and 2020, the Company recognized approximately $146,000 and $1.0 million, respectively, in revenue related to the collaboration agreement in the Condensed Statements of Operations. The revenue for the nine months ended September 30, 2020 included a milestone payment of $925,000 upon the 12 th Adimab, LLC In October 2015, Fortress entered into a collaboration agreement with Adimab , LLC (“Adimab”) to discover and optimize antibodies using their proprietary core technology platform. Under this agreement, Adimab optimized cosibelimab (formerly referred to as CK-301), the Company’s anti-PD-L1 antibody which it originally licensed from Dana-Farber. In January 2019, Fortress transferred the rights to the optimized antibody to the Company, and Checkpoint entered into a collaboration agreement directly with Adimab on the same day. Under the terms of the agreement, Adimab is eligible to receive payments up to an aggregate of approximately $7.1 million upon the Company’s successful achievement of certain clinical development and regulatory milestones, of which $4.8 million are due upon various filings for regulatory approvals to commercialize the product. In addition, Adimab is eligible to receive royalty payments based on a tiered low single digit percentage of net sales. NeuPharma, Inc. In March 2015, Fortress entered into an exclusive license agreement with NeuPharma, Inc. (“NeuPharma”) to develop and commercialize novel irreversible, 3rd generation EGFR inhibitors, including olafertinib (formerly CK-101), on a worldwide basis other than certain Asian countries. On the same date, Fortress assigned all of its right and interest in the EGFR inhibitors to the Company. Under the terms of the license agreement, the Company paid NeuPharma an up-front licensing fee of $1.0 million, and NeuPharma is eligible to receive payments of up to an aggregate of approximately $40.0 million upon the Company’s successful achievement of certain clinical development and regulatory milestones in up to three indications, of which $22.5 million are due upon various regulatory approvals to commercialize the products. In addition, NeuPharma is eligible to receive payments of up to an aggregate of $40.0 million upon the Company’s successful achievement of certain sales milestones based on aggregate net sales, in addition to royalty payments based on a tiered mid to high-single digit percentage of net sales. Jubilant Biosys Limited In May 2016, the Company entered into a license agreement with Jubilant Biosys Limited (“Jubilant”), whereby the Company obtained an exclusive, worldwide license to Jubilant’s family of patents covering compounds that inhibit BET proteins such as BRD4, including CK-103. Under the terms of the license agreement, the Company paid Jubilant an up-front licensing fee of $2.0 million, and Jubilant is eligible to receive payments up to an aggregate of approximately $89.0 million upon the Company’s successful achievement of certain clinical development and regulatory milestones, of which $59.5 million are due upon various regulatory approvals to commercialize the products. In addition, Jubilant is eligible to receive payments up to an aggregate of $89.0 million upon the Company’s successful achievement of certain sales milestones based on aggregate net sales, in addition to royalty payments based on a tiered low to mid-single digit percentage of net sales. In connection with the license agreement with Jubilant, the Company entered into a sublicense agreement with TGTX, a related party, to develop and commercialize the compounds licensed in the field of hematological malignancies, while the Company retains the right to develop and commercialize these compounds in the field of solid tumors. Under the terms of the sublicense agreement, TGTX paid the Company $1.0 million, representing an upfront licensing fee, and the Company is eligible to receive substantive potential milestone payments up to an aggregate of approximately $87.2 million upon TGTX’s successful achievement of clinical development and regulatory milestones. This is comprised of up to approximately $25.5 million upon TGTX’s successful completion of three clinical development milestones for two licensed products, and up to approximately $61.7 million upon the achievement of five regulatory approvals and first commercial sales in specified territories for two licensed products. In addition, the Company is eligible to receive potential milestone payments up to an aggregate of $89.0 million upon TGTX’s successful achievement of certain sales milestones based on aggregate net sales by TGTX, for two licensed products, in addition to royalty payments based on a mid-single digit percentage of net sales by TGTX. TGTX also pays the Company 50% of IND enabling costs and patent expenses. For the three months ended September 30, 2021 and 2020, the Company recognized approximately $28,000 and $21,000, respectively, in revenue related to the sublicense agreement in the Condensed Statements of Operations. For the nine months ended September 30, 2021 and 2020, the Company recognized approximately $106,000 and $67,000, respectively, in revenue related to the sublicense agreement in the Condensed Statements of Operations. The collaborations with TGTX each contain single material performance obligations under Topic 606, which is the granting of a license that is functional intellectual property. The Company’s performance obligation was satisfied at the point in time when TGTX had the ability to use and benefit from the right to use the intellectual property. The performance obligations of the original agreements were satisfied prior to the adoption of Topic 606. The performance obligation of the amendment to the collaboration agreement was satisfied in June 2019. The milestone payments are based on successful achievement of clinical development, regulatory, and sales milestones. Because these payments are contingent on the occurrence of a future event, they represent variable consideration and are constrained and included in the transaction price only when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The sales-based royalty payments are recognized as revenue when the subsequent sales occur. The Company also receives variable consideration for certain research and development, out-of-pocket material costs, and patent maintenance related activities. These amounts are dependent upon the Company’s actual expenditures under the collaborations and are constrained and included in the transaction price only when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. As this revenue relates to an already satisfied performance obligation, it is recognized approximately when the amounts become due. For the nine months ended September 30, 2021, the Company did not receive any milestone or royalty payments.

Related Party Agreements

Related Party Agreements	9 Months Ended
Related Party Agreements	Sep. 30, 2021
Related Party Agreements
Related Party Agreements	Note 4 – Related Party Agreements Founders Agreement and Management Services Agreement with Fortress Effective March 17, 2015, the Company entered into a Founders Agreement with Fortress, which was amended in July 2016 and October 2017. The Founders Agreement provides, that in exchange for the time and capital expended in the formation of Checkpoint and the identification of specific assets the acquisition of which resulted in the formation of a viable emerging growth life science company, the Company assumed $2.8 million in debt that Fortress accumulated under a promissory note through National Securities Corporation for expenses and costs of forming Checkpoint. Further, the Company shall: (i) issue annually to Fortress, on January 1 of each year, shares of common stock equal to two and one-half percent (2.5%) of the fully diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Checkpoint’s voting equity, equal to two and one-half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Checkpoint’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), Checkpoint will pay a one-time change in control fee equal to five times (5x) the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%). The Founders Agreement has a term of fifteen years, after which it automatically renews for one-year periods unless Fortress gives the Company notice of termination. The Founders Agreement will also automatically terminate upon a change of control. Effective March 17, 2015, the Company entered into a Management Services Agreement (the “MSA”) with Fortress. Pursuant to the terms of the MSA, for a period of five (5) years, Fortress will render advisory and consulting services to the Company. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Checkpoint’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of the Company with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). The Company is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, the Company is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of the Company’s actions or inactions based upon their advice. Fortress and its affiliates, including all members of its Board of Directors, have been contractually exempt from fiduciary duties to the Company relating to corporate opportunities. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $0.5 million (the “Annual Consulting Fee”), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each year, provided, however, that such Annual Consulting Fee shall be increased to $1.0 million for each calendar year in which the Company has net assets in excess of $100 million at the beginning of the calendar year. The MSA shall be automatically extended for additional five-year periods unless Fortress or the Company provides notice to the other party of its desire not to automatically extend the term. For the three months ended September 30, 2021 and 2020, the Company recognized $125,000 in expense on its Condensed Statements of Operations related to the MSA. For the nine months ended September 30, 2021 and 2020, the Company recognized $375,000 in expense on its Condensed Statements of Operations related to the MSA. Caribe BioAdvisors, LLC In December 2016, the Company entered into an advisory agreement effective January 1, 2017 with Caribe BioAdvisors, LLC (“Caribe”), owned by Michael Weiss, to provide the advisory services of Mr. Weiss as Chairman of the Board. Pursuant to the agreement, Caribe will be paid an annual cash fee of $60,000, in addition to any and all annual equity incentive grants paid to members of the board. For the three months ended September 30, 2021 and 2020, the Company recognized approximately $28,000 in expense in its Condensed Statements of Operations related to the advisory agreement, including approximately $13,000 in expense related to annual equity incentive grants. For the nine months ended September 30, 2021 and 2020, the Company recognized approximately $83,000 and $84,000, respectively, in expense in its Condensed Statements of Operations related to the advisory agreement, including approximately $37,000 and $39,000, respectively, in expense related to annual equity incentive grants.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2021
Commitments and Contingencies
Commitments and Contingencies	Note 5 – Commitments and Contingencies Leases The Company is not a party to any leases for office space or equipment. License Agreements The Company has undertaken to make contingent milestone payments to the licensors of its portfolio of product candidates. In addition, the Company would pay royalties to such licensors based on a percentage of net sales of each product candidate following regulatory marketing approval (See Note 3). Litigation The Company recognizes a liability for a contingency when it is probable that liability has been incurred and when the amount of loss can be reasonably estimated. When a range of probable loss can be estimated, the Company accrues the most likely amount of such loss, and if such amount is not determinable, then the Company accrues the minimum of the range of probable loss. As of September 30, 2021, and December 31, 2020, there was no litigation against the Company.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2021
Stockholders' Equity
Stockholders' Equity	Note 6 – Stockholders’ Equity Common Stock At the Company’s 2021 Annual Meeting of Stockholders held on June 9, 2021, its stockholders approved an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock available to issue by 40,000,000 to 135,000,000 with a par value of $0.0001 per share, of which 7,000,000 shares are designated as “Class A common stock.” The amendment was filed with the Secretary of State of the State of Delaware on June 10, 2021. As of September 30, 2021 and December 31, 2020, there were 7,000,000 shares of Class A common stock issued and outstanding to Fortress. Dividends are to be distributed pro-rata to the Class A and common stockholders. The holders of common stock are entitled to one vote per share of common stock held. The Class A common stockholders are entitled to a number of votes per share equal to 1.1 times a fraction, the numerator of which is the sum of the shares of outstanding common stock and the denominator of which is the number of shares of Class A common stock. Accordingly, the holder of shares of Class A common stock will be able to control or significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. Each share of Class A common stock is convertible, at the option of the holder thereof, into one (1) fully paid and non-assessable share of common stock subject to adjustment for stock splits and combinations. In November 2020, the Company filed a shelf registration statement on Form S-3 (the “S-3”), which was declared effective in December 2020. Under the S-3, the Company may sell up to a total of $100 million of its securities. In connection with the S-3, the Company entered into an ATM with Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC (each an “Agent” and collectively, the “Agents”) relating to the sale of shares of common stock. Under the ATM, the Company pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock. During the nine months ended September 30, 2021, the Company sold a total of 10,860,983 shares of common stock under an ATM, at an average selling price of $3.42 per share, resulting in aggregate total gross proceeds of approximately $37.2 million and net proceeds of approximately $36.3 million after deducting approximately $0.9 million in commissions and other transaction costs. Pursuant to the Founders Agreement, the Company issued to Fortress 2.5% of the aggregate number of shares of common stock issued in the offering noted above. Accordingly, the Company issued 271,515 shares of common stock to Fortress and recorded expense of approximately $926,000 related to these stock grants, which is included in general and administrative expenses in the Company’s Condensed Statements of Operations for the nine months ended September 30, 2021. Pursuant to the Founders Agreement, the Company issued 1,742,449 shares of common stock to Fortress for the Annual Equity Fee, representing 2.5% of the fully diluted outstanding equity of Checkpoint on January 1, 2021 (see Notes 2 and 4). As of September 30, 2021, approximately $58.7 million of securities remain available for sale under the S-3. The Company may offer the securities under the S-3 from time to time in response to market conditions or other circumstances if it believes such a plan of financing is in the best interests of its stockholders. Equity Incentive Plan The Company has in effect the Amended and Restated 2015 Incentive Plan (“2015 Incentive Plan”). The 2015 Incentive Plan was adopted in March 2015 by our stockholders. Under the 2015 Incentive Plan, the compensation committee of the Company’s board of directors is authorized to grant stock-based awards to directors, officers, employees and consultants. An amendment to the 2015 Incentive Plan was approved by stockholders in June 2020 to increase the shares available for issuance to 9,000,000 shares. The plan expires 10 years from the effective date of the amendment and limits the term of each option to no more than 10 years from the date of grant. As of September 30, 2021, 3,319,453 shares are available for issuance under the 2015 Incentive Plan. Restricted Stock Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted stock award activity for the nine months ended September 30, 2021: Weighted Average Number of Grant Date Fair Shares Value Non-vested at December 31, 2020 3,869,896 $ 3.61 Granted 919,012 2.70 Vested (548,040) 4.17 Non-vested at September 30, 2021 4,240,868 $ 3.34 As of September 30, 2021, there was $3.1 million of total unrecognized compensation cost related to non-vested restricted stock, which is expected to be recognized over a weighted-average period of 1.8 years. This amount does not include, as of September 30, 2021, 333,334 shares of restricted stock outstanding which are performance-based and vest upon achievement of certain corporate milestones. The expense is recognized over the vesting period of the award. Stock-based compensation for milestone awards will be measured and recorded if and when it is probable that the milestone will be achieved. Stock Options The following table summarizes stock option award activity for the nine months ended September 30, 2021: Weighted Average Remaining Weighted Average Contractual Life Stock Options Exercise Price (in years) Outstanding as of December 31, 2020 220,000 $ 3.20 8.04 Granted 50,000 2.85 Outstanding as of September 30, 2021 270,000 $ 3.14 7.69 Vested and exercisable as of September 30, 2021 50,000 $ 2.56 7.69 Upon the exercise of stock options, the Company will issue new shares of its common stock. The Company used the Black-Scholes option pricing model for determining the estimated fair value of stock-based compensation related to stock options. The table below summarizes the assumptions used: For the Nine Months Ended September 30, 2021 2020 Risk-free interest rate 1.04% - 1.50 % 0.65% - 1.02 % Expected dividend yield — — Expected term in years 10.0 10.0 Expected volatility 100.65% - 102.71 % 101.27% - 104.60 % Warrants A summary of warrant activities for the nine months ended September 30, 2021 is presented below: Weighted Average Remaining Weighted Average Contractual Life Warrants Exercise Price (in years) Outstanding as of December 31, 2020 57,515 $ 5.39 1.22 Expired (44,324) 7.00 Outstanding as of September 30, 2021 13,191 $ 0.00 4.08 Upon the exercise of warrants, the Company will issue new shares of its common stock. Stock-Based Compensation The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020 ($ in thousands): For the three months ended September 30, For the nine months ended September 30, 2021 2020 2021 2020 Research and development $ 161 $ 157 $ 480 $ 462 General and administrative 618 568 1,839 1,633 Total stock-based compensation expense $ 779 $ 725 $ 2,319 $ 2,095

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
Accounts Payable and Accrued Expenses	Sep. 30, 2021
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	Note 7 - Accounts Payable and Accrued Expenses At September 30, 2021 and December 31, 2020, accounts payable and accrued expenses consisted of the following ($ in thousands): September 30, December 31, 2021 2020 Accounts payable $ 7,812 $ 3,438 Accrued compensation 452 535 Research and development 3,518 2,009 Other 282 385 Total accounts payable and accrued expenses $ 12,064 $ 6,367

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2021
Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Exchange Act. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. They may not include all of the information and notes required by GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2020, which were included in the Company’s Form 10-K, and filed with the SEC on March 12, 2021. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Other Receivables - Related Party	Other Receivables - Related Party Other receivables consist of amounts due to the Company from TG Therapeutics, Inc. (“TGTX”), a related party, and are recorded at the invoiced amount.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies. In accordance with Accounting Standards Codification (“ASC”) 730-10-25-1, Research and Development
Annual Equity Fee	Annual Equity Fee Under the Founders Agreement with Checkpoint dated March 17, 2015, and amended and restated in July 2016 and October 2017 (the “Founders Agreement”), Fortress is entitled to an annual equity fee on January 1 of each year equal to 2.5% of fully diluted outstanding equity, payable in Checkpoint common shares (“Annual Equity Fee”). The Annual Equity Fee was part of the consideration payable for formation of the Company, identification of certain assets, including the license contributed to Checkpoint by Fortress (see Note 4). The Company records the Annual Equity Fee in connection with the Founders Agreement with Fortress as contingent consideration. Contingent consideration is recorded when probable and reasonably estimable. Due to the nature of the Company’s assets and stage of development, future share prices and shares outstanding cannot be estimated prior to the issuance of the Annual Equity Fee. Due to these uncertainties, the Company has concluded that it is unable to reasonably estimate the contingent consideration until shares are actually issued on January 1 of each year. Pursuant to the Founders Agreement, the Company issued 1,742,449 shares of common stock to Fortress for the Annual Equity Fee, representing 2.5% of the fully diluted outstanding equity of Checkpoint on January 1, 2021. Because the number of outstanding shares issuable to Fortress was determinable on January 1, 2021 prior to the issuance of the December 31, 2020 financial statements, the Company recorded approximately $4.6 million in research and development expense and a credit to Common shares issuable - Founders Agreement during the year ended December 31, 2020.
Stock-Based Compensation Expenses	Stock-Based Compensation Expenses The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the Condensed Statements of Operations based upon the underlying individual’s role at the Company.
Fair Value Measurement	Fair Value Measurement The Company follows the accounting guidance in ASC 820 for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable and accrued expenses.
Revenue from Contracts with Customers	Revenue from Contracts with Customers The Company recognizes revenue under ASC 606, “ Revenue from Contracts with Customers ● Step 1: Identify the contract with the customer. ● Step 2: Identify the performance obligations in the contract. ● Step 3: Determine the transaction price. ● Step 4: Allocate the transaction price to the performance obligations in the contract. ● Step 5: Recognize revenue when the company satisfies a performance obligation. In order to identify the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or service that is distinct. A performance obligation meets ASC 606’s definition of a “distinct” good or service (or bundle of goods or services) if both of the following criteria are met: ● the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and ● the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. When determining the transaction price, an entity must consider the effects of all of the following: ● variable consideration; ● constraining estimates of variable consideration; ● the existence of a significant financing component in the contract; ● noncash consideration; and ● consideration payable to a customer. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized when that performance obligation is satisfied, at a point in time or over time as appropriate. Revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property is recognized only when (or as) the later of the following events occurs: a. the subsequent sale or usage occurs; and b. the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). Incremental contract costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as services are provided to a customer.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not to be sustained upon audit, the Company recognizes the largest amount with a greater than 50% likelihood of being realized. The Company does not recognize any portion of the benefit for tax positions that are not more likely than not to be sustained upon audit. As of September 30, 2021 and December 31, 2020, the Company determined, based upon available evidence, that it is more likely than not that the net deferred tax asset will not be realized and, accordingly, has provided a full valuation allowance against its net deferred tax asset.
Net Loss per Share	Net Loss per Share Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class A common stock pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of stock options and warrants, as their inclusion would be anti-dilutive. The following table summarizes potentially dilutive securities outstanding at September 30, 2021 and 2020 that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive: September 30, 2021 2020 Warrants (Note 6) 13,191 3,224,455 Stock options (Note 6) 270,000 220,000 Unvested restricted stock (Note 6) 4,240,868 4,013,199 Total 4,524,059 7,457,654
Coronavirus Aid, Relief and Economic Security Act ("CARES Act")	Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. The CARES Act did not have a material impact on the Company’s income tax provision. The Company will continue to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows. On December 27, 2020, the President of the United States signed the Consolidated Appropriations Act, 2021 (“Consolidated Appropriations Act”) into law. The Consolidated Appropriations Act is intended to enhance and expand certain provisions of the CARES Act, allows for the deductions of expenses related to the Payroll Protection Program funds received by companies, and provides an update to meals and entertainment expensing for 2021. The Consolidated Appropriations Act did not have a material impact to the Company’s income tax provision for 2020 and the Company does not believe it will have a material impact on its income tax provision for 2021. The Company will continue to evaluate the impact of the Consolidated Appropriations Act on its financial position, results of operations and cash flows.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “ Financial Instruments – Credit Losses In August 2020, the FASB issued ASU No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Recently Adopted Accounting Standards In December 2019, the FASB issued ASU No. 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
Significant Accounting Policies (Tables)	Sep. 30, 2021
Significant Accounting Policies
Schedule of potentially dilutive securities outstanding, that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	September 30, 2021 2020 Warrants (Note 6) 13,191 3,224,455 Stock options (Note 6) 270,000 220,000 Unvested restricted stock (Note 6) 4,240,868 4,013,199 Total 4,524,059 7,457,654

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2021
Stockholders' Equity
Summary of restricted stock award activity	Weighted Average Number of Grant Date Fair Shares Value Non-vested at December 31, 2020 3,869,896 $ 3.61 Granted 919,012 2.70 Vested (548,040) 4.17 Non-vested at September 30, 2021 4,240,868 $ 3.34
Summary of stock option award activity	The following table summarizes stock option award activity for the nine months ended September 30, 2021: Weighted Average Remaining Weighted Average Contractual Life Stock Options Exercise Price (in years) Outstanding as of December 31, 2020 220,000 $ 3.20 8.04 Granted 50,000 2.85 Outstanding as of September 30, 2021 270,000 $ 3.14 7.69 Vested and exercisable as of September 30, 2021 50,000 $ 2.56 7.69
Summary of stock options assumptions used	For the Nine Months Ended September 30, 2021 2020 Risk-free interest rate 1.04% - 1.50 % 0.65% - 1.02 % Expected dividend yield — — Expected term in years 10.0 10.0 Expected volatility 100.65% - 102.71 % 101.27% - 104.60 %
Summary of warrant activities	A summary of warrant activities for the nine months ended September 30, 2021 is presented below: Weighted Average Remaining Weighted Average Contractual Life Warrants Exercise Price (in years) Outstanding as of December 31, 2020 57,515 $ 5.39 1.22 Expired (44,324) 7.00 Outstanding as of September 30, 2021 13,191 $ 0.00 4.08
Summary of stock-based compensation expense	The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020 ($ in thousands): For the three months ended September 30, For the nine months ended September 30, 2021 2020 2021 2020 Research and development $ 161 $ 157 $ 480 $ 462 General and administrative 618 568 1,839 1,633 Total stock-based compensation expense $ 779 $ 725 $ 2,319 $ 2,095

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
Accounts Payable and Accrued Expenses (Tables)	Sep. 30, 2021
Accounts Payable and Accrued Expenses
Schedule of accounts payable and accrued expenses	At September 30, 2021 and December 31, 2020, accounts payable and accrued expenses consisted of the following ($ in thousands): September 30, December 31, 2021 2020 Accounts payable $ 7,812 $ 3,438 Accrued compensation 452 535 Research and development 3,518 2,009 Other 282 385 Total accounts payable and accrued expenses $ 12,064 $ 6,367

Organization and Description _2

Organization and Description of Business Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accumulated deficit	$ (170,106)	$ (143,192)
At the Market Offering
Number of shares sold	10,860,983
Average selling price per share	$ 3.42
Aggregate total gross proceeds from shares sold	$ 37,200
Net proceeds from shares sold	36,300
Commissions and other transaction costs	$ 900

Significant Accounting Polici_4

Significant Accounting Policies - Net Loss per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	4,524,059	7,457,654
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	13,191	3,224,455
Stock options (Note 6) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	270,000	220,000
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	4,240,868	4,013,199

Significant Accounting Polici_5

Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	Jan. 01, 2021	Sep. 30, 2021	Dec. 31, 2020	Mar. 17, 2015
Percentage of annual equity fee				2.50%
Fortress Biotech, Inc
Percentage of annual equity fee	2.50%	2.50%
Number of common stock shares issued	1,742,449	271,515
Research and development
Value of common stock shares issued			$ 4.6

License Agreements (Details)

License Agreements (Details) - USD ($)	Sep. 30, 2015	May 11, 2015	Jun. 30, 2019	May 31, 2016	Mar. 31, 2015	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Commercial Sales In Specified Territories [Member] \| PD-L1 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						$ 21,500,000		$ 21,500,000
Neupharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment of upfront licensing fees					$ 1,000,000
Neupharma [Member] \| Additional Sales Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						40,000,000		40,000,000
Neupharma [Member] \| Clinical and Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						40,000,000		40,000,000
Neupharma [Member] \| Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						22,500,000		22,500,000
Dana-Farber [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of shares of common stock granted	136,830	500,000
Ownership percentage		5.00%
Cash in exchange for common shares		$ 10,000,000
Payment for non-refundable milestone payments									$ 925,000
Maintenance fee								50,000
Value of common stock shares issued	$ 600,000	$ 32,500
Sale price per share		$ 0.065
Dana-Farber [Member] \| First Commercial Sale Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						21,500,000		21,500,000
Dana-Farber [Member] \| Additional Sales Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						60,000,000		60,000,000
Jubilant Biosys Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment of upfront licensing fees				$ 2,000,000
Revenue recognition milestone revenue recognized						$ 28,000	$ 21,000	$ 106,000	67,000
Proceeds from upfront fees				$ 1,000,000
Research and development cost						50.00%		50.00%
Jubilant Biosys Ltd [Member] \| Clinical and Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						$ 89,000,000		$ 89,000,000
Jubilant Biosys Ltd [Member] \| Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						59,500,000		59,500,000
Jubilant Biosys Ltd [Member] \| Five Regulatory Approvals And First Commercial Sales [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						61,700,000		61,700,000
Jubilant Biosys Ltd [Member] \| Sale Millstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						89,000,000		89,000,000
Maximum potential milestone payments						89,000,000		89,000,000
Jubilant Biosys Ltd [Member] \| Clinical Development and Regulatory Milestones [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						87,200,000		87,200,000
Adimab LLC [Member] \| Clinical and Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						7,100,000		7,100,000
Adimab LLC [Member] \| Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						4,800,000		4,800,000
Collaboration Agreement With TGTX [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone revenue recognized						1,000	$ 7,000	146,000	$ 1,000,000
Proceeds from upfront fees			$ 1,000,000		$ 500,000
Collaboration Agreement With TGTX [Member] \| First Commercial Sale Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						14,500,000		14,500,000
Collaboration Agreement With TGTX [Member] \| First Commercial Sale Milestone [Member] \| PD-L1 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum potential milestone payments						27,600,000		27,600,000
Collaboration Agreement With TGTX [Member] \| Clinical and Development Milestone [Member] \| PD-L1 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						7,000,000		7,000,000
Collaboration Agreement With TGTX [Member] \| Commercial Sales In Specified Territories [Member] \| PD-L1 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						19,200,000		19,200,000
Collaboration Agreement With TGTX [Member] \| Clinical Development and Regulatory Milestones [Member] \| PD-L1 [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						8,400,000		8,400,000
Sublicense Agreement with TGTX [Member] \| Clinical and Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition milestone payments						$ 25,500,000		$ 25,500,000

Related Party Agreements (Detai

Related Party Agreements (Details)	Mar. 17, 2015USD ($)item	Dec. 31, 2016USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Management Services Agreement
Related Party Transaction [Line Items]
Number of period	5 years
Annual consulting fee	$ 500,000
Increase in annual consulting fee	1,000,000
Excess in net assets value	100,000,000
Costs and expenses, related party			$ 125,000	$ 125,000	$ 375,000	$ 375,000
Fortress Biotech, Inc \| Founders Agreement
Related Party Transaction [Line Items]
Long term debt	$ 2,800,000
Issuance of common stock, percentage of outstanding diluted equity	2.50%
Number of business days	5 days
Voting equity, percentage of equity or debt financing	2.50%
Cash fee, percentage of annual net sales	4.50%
Cash fees, maximum number of days	90 days
Control fees, number of times \| item	5
Control fees, monthly net sales	12 months
Cash fee, percentage of monthly net sales	4.50%
Agreement term	15 years
Caribe Bioadvisors LLC
Related Party Transaction [Line Items]
Costs and expenses, related party			28,000	28,000	83,000	84,000
Annual advisory service fee		$ 60,000
Caribe Bioadvisors LLC \| Equity Incentive Grants
Related Party Transaction [Line Items]
Costs and expenses, related party			$ 13,000	$ 13,000	$ 37,000	$ 39,000

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock (Details) - Unvested restricted stock	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Nonvested beginning balance \| shares	3,869,896
Number of shares, Granted \| shares	919,012
Number of shares, Vested \| shares	(548,040)
Number of shares, Nonvested ending balance \| shares	4,240,868
Weighted Average Exercise Price, Nonvested beginning balance \| $ / shares	$ 3.61
Weighted Average Grant Date Fair Value, Granted \| $ / shares	2.70
Weighted Average Grant Date Fair Value, Vested \| $ / shares	4.17
Weighted Average Exercise Price, Nonvested ending balance \| $ / shares	$ 3.34

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options (Details) - Options - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, Outstanding (beginning)	220,000
Stock options, Granted	50,000
Stock options, Outstanding (ending)	270,000	220,000
Stock options, Vested and exercisable as of June 30, 2021	50,000
Weighted Average Exercise Price, Outstanding (beginning)	$ 3.20
Weighted Average Exercise Price, Granted	2.85
Weighted Average Exercise Price, Outstanding (ending)	3.14	$ 3.20
Weighted Average Exercise Price, Vested and exercisable as of June 30, 2021	$ 2.56
Weighted Average Remaining Contractual Life, Outstanding (in years)	7 years 8 months 8 days	8 years 14 days
Weighted Average Remaining Contractual Life, Vested and exercisable (in years)	7 years 8 months 8 days

Stockholders' Equity - Option p

Stockholders' Equity - Option pricing model (Details)	9 Months Ended
Stockholders' Equity - Option pricing model (Details)	Sep. 30, 2021	Sep. 30, 2020
Stockholders' Equity
Risk-free interest rate, Minimum	1.04%	0.65%
Risk-free interest rate, Maximum	1.50%	1.02%
Expected term in years	10 years	10 years
Expected volatility, Minimum	100.65%	101.27%
Expected volatility, Maximum	102.71%	104.60%

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - Warrants - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants, Outstanding beginning balance	57,515
Warrants, Expired	(44,324)
Warrants, Outstanding ending balance	13,191	57,515
Weighted Average Exercise Price, Nonvested beginning balance	$ 5.39
Weighted Average Exercise Price, Expired	7
Weighted Average Exercise Price, Nonvested ending balance	$ 0	$ 5.39
Weighted Average Remaining Contractual Life, outstanding (in years)	4 years 29 days	1 year 2 months 19 days

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 779	$ 725	$ 2,319	$ 2,095
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	161	157	480	462
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 618	$ 568	$ 1,839	$ 1,633

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	Jan. 01, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 09, 2021	Dec. 31, 2020	Nov. 30, 2020	Jun. 30, 2020	Mar. 17, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized		135,000,000		135,000,000		40,000,000	95,000,000
Common Stock, Increase in authorized shares (in shares)						135,000,000
Common stock, par or stated value per share		$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares issued		76,214,398		76,214,398			62,420,439
Common stock, shares outstanding		76,214,398		76,214,398			62,420,439
Shelf registration statement, maximum authorized securities								$ 100,000,000
Percentage of annual equity fee										2.50%
Issuance of common shares, net of offering costs - At-the-market offering		$ 1,542,000	$ 5,813,000	$ 36,259,000	$ 8,417,000
Issuance of common shares - Founders Agreement		39,000	$ 731,000	926,000	$ 797,000
Shelf registration statement remaining authorized securities		58,700,000		58,700,000
Non-vested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested		$ 3,100,000		$ 3,100,000
Weighted average period (in years)				1 year 9 months 18 days
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding non-vested		333,334		333,334
2015 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance Authorized									9,000,000
Plans expires (in years)				10 years
Shares are available for issuance		3,319,453		3,319,453
At the Market Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares sold				10,860,983
Sale price per share		$ 3.42		$ 3.42
Aggregate total gross proceeds from shares sold				$ 37,200,000
Net proceeds from the offering				$ 36,300,000
Stock issued during period shares common shares for at the market offering				10,860,983
Stock issued during period value common shares for at the market offering gross				$ 37,200,000
Issuance of common shares, net of offering costs - At-the-market offering				36,300,000
Commissions and other transaction costs				$ 900,000
Fortress Biotech, Inc
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares sold	1,742,449			271,515
Percentage of annual equity fee	2.50%	2.50%		2.50%
Issuance of common shares - Founders Agreement				$ 926,000
Agent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Commission rate		3.00%		3.00%
Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized						7,000,000
Common stock, shares issued		7,000,000		7,000,000			7,000,000
Common stock, shares outstanding		7,000,000		7,000,000			7,000,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accounts Payable and Accrued Expenses
Accounts payable	$ 7,812	$ 3,438
Accrued compensation	452	535
Research and development	3,518	2,009
Other	282	385
Total accounts payable and accrued expenses	$ 12,064	$ 6,367